Introduction Antiplatelet Agents ADP Receptor Antagonists.

Slides:

Advertisements

Similar presentations

Invasive Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATelet Inhibition and patient Outcomes trial Outcomes in.

Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI 261 EVREV 2: Daniel Pichel COI # 513 Taskforce: ACS ACS 335: Pre-hospital ADP- Receptor.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.

Nick Alp Milton Keynes Hospital NHS FT Oxford Radcliffe NHS Trust Bleeding risks in the major trials – It does matter.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

New Anti-platelet Agents

_________________ Caitlin M. Gibson, PharmD, BCPS

Heparin Should be the First-line Therapy for Patients with ACS/AMI

Adnan K. Chhatriwalla, MD Saint-Luke’s Mid America Heart Institute

Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

Should We Preload STEMI Patients with Antiplatelet Therapy?

The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Achieving Long-Term Protection Post-MI

Thrombosis, Cancer, and NOACs

PAD Patients vs Post-ACS Patients:

Figure 3 Metabolism pathway of antiplatelet agents

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

New Perspectives in AF and PCI: Implications for the Practicing Physician.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Nat. Rev. Cardiol. doi: /nrcardio

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

What Has Been Tried and What Is True?

Surveying the Safety of NOACs in the Real World

Tailoring Antiplatelet Therapy in PCI

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Nat. Rev. Cardiol. doi: /nrcardio

Current State of Equipoise: The New Era of Novel Oral Anticoagulants

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

New LDL-C Lipid Targets

Dos and Don’ts for High-Risk Elderly Patients With AF

Nat. Rev. Cardiol. doi: /nrcardio

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

Cancer-Associated Thrombosis

CAD and HF Often Coexist

What oral antiplatelet therapy would you choose?

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Roberta Rossini et al. JCIN 2018;11:

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Section C: Clinical trial update: Oral antiplatelet therapy

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Translating Data From Trial to Practice

Presentation transcript:

Introduction

Antiplatelet Agents

ADP Receptor Antagonists

CURE Reduction in Cardiovascular Events With Clopidogrel

TRITON-TIMI 38 Risk Reduction Prasugrel vs Clopidogrel

PLATO Major Events: Ticagrelor vs Clopidogrel

Onset of Action

Randomized Trials of Antiplatelet Agents TRITON-TIMI 38 and PLATO

TRANSLATE-ACS

After the Patient Goes Home…

Antiplatelet Use After PCI

Hospitalized Bleeding

TRANSLATE-ACS Factors Associated With In-hospital Switch From 1st- to 2nd-generation ADP Receptor Inhibitor

TRANSLATE-ACS Factors Associated With In-hospital Switch From 2nd to 1st -generation ADP Receptor Inhibitor

Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel

TRITON-TIMI 38 Risk Reduction: Prasugrel vs Clopidogrel

TRANSLATE-POPS Design

POPS – Change in Treatment

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)